Actelion’s Board and management are committed to ensuring that responsible business and sustainability considerations are integrated into everyday business thinking and decision-making throughout Actelion. The Nominating and Governance Committee oversees Actelion’s sustainability efforts and is briefed quarterly by the Chief Compliance Officer on the progress we make.
For Actelion, the past year was one of genuine progress. Our sales and earnings increased, driven by the continued highly successful Opsumit® launch, and our pipeline advanced. At the end of 2015, over 65,000 patients around the globe were benefiting from our drugs.
2015 was also a year where we strengthened our commitment to sustainability reporting. Increasingly, stakeholders are considering our sustainability performance in their employment, investment and other decisions.
We aim to disclose our performance on material issues in a way that highlights the relationship between business success and sustainability considerations in our operations. We have changed the name of our Corporate Social Responsibility (CSR) Report to Sustainability Report, to better reflect our broader view of the topics that matter to our stakeholders and to us.
Over the past year, we have engaged our many stakeholders, including patients, healthcare providers, employees, and investors, to help us validate the issues critical to our sustainability strategy and reporting.
Based on their feedback, we have defined four key areas that form the basis of our sustainability management and reporting: Patients, Our Behavior, Our People, and Environment.
We will continue to advance our reporting and disclosures on these topics and look forward to sharing our progress with all our stakeholders.
We aim to provide greater transparency, applying the highest standards of integrity across the entire company.
Our employees are the foundation of our business, contributing to our success as a global biopharmaceutical company.